Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06598943 · ClinicalTrials.gov registry record · Phase 2

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

A Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 2
Development phase
140
Enrollment target
20
Study locations

NCT06598943 is a Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 140 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06598943, a Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 2
Development phase
140 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

Conditions Studied

Ulcerative Colitis Ulcerative Colitis Chronic

Interventions

  • DRUG Placebo
  • DRUG Mirikizumab
  • DRUG Eltrekibart

Study Locations (20)

California

  • Erick Alayo Medical Corp/Gastro SB Clinic - Chula Vista
  • Southern California GI and Liver Centers (SCLC) - Coronado
  • Valley View Research - Garden Grove
  • Om Research, LLC - Lancaster
  • United Medical Doctors - Los Alamitos
  • Clinnova Research - Orange
  • Prospective Research Innovations - Rancho Cucamonga
  • Clinical Trials Management Services, LLC - Thousand Oaks
  • Om Research LLC - Victorville

Florida

  • Novum Research, LLC - Clermont
  • I.V.A.M. Clinical & Investigational Center, LLC - Doral
  • Florida Research Institute - Lakewood Rch
  • Well Pharma Medical Research Corp. - Miami
  • Reserka - Miami
  • Digestive Disease Consultants DDCJAX - Orange Park

Arkansas

  • Applied Research Center of Arkansas - Little Rock
  • Preferred Research Partners - Little Rock

Arizona

  • AZ Gastro Care - Chandler - Chandler

Colorado

  • Peak Gastroenterology Associates - Colorado Springs

Connecticut

  • Medical Research Center of Connecticut, LLC - Hamden

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2024-10-10
Est. Completion 2028-09
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06598943

The ClinicalTrials.gov registry entry for NCT06598943 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (93% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06598943 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06598943 about?

NCT06598943 is a clinical study titled "A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis". The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

What is the current status of trial NCT06598943?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2024-10-10. Estimated completion is 2028-09.

What conditions does trial NCT06598943 study?

This clinical trial studies the following conditions: Ulcerative Colitis, Ulcerative Colitis Chronic.

What interventions are being tested in trial NCT06598943?

The interventions under investigation include: Placebo (DRUG), Mirikizumab (DRUG), Eltrekibart (DRUG).

Who is sponsoring clinical trial NCT06598943?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06598943 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis

All registered trials for this condition

Ulcerative Colitis Chronic

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.